NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

Rhea-AI Summary

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, along with its wholly-owned subsidiary HOPE Therapeutics, announced their participation in an upcoming H.C. Wainwright @ Home fireside discussion.

The event is scheduled for Tuesday, April 22, 2025, at 10:00 AM EDT. Dr. Jonathan Javitt, who serves as both the Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will engage in a fireside chat led by HCW Senior Biotech Analyst Vernon Bernardino.

Interested investors can access the webcast through the company's investor relations website at ir.nrxpharma.com/events or by contacting their HC Wainwright representative for registration.

WILMINGTON, Del., April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that it will participate in an H.C. Wainwright @ Home fireside discussion, taking place on Tuesday, April 22, 2025 at 10AM EDT.

Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals, and Co-CEO of HOPE Therapeutics, will participate in a fireside chat lead by HCW Senior Biotech Analyst, Vernon Bernardino.

Event Details:

• Event: HCW @ Home with NRx Pharmaceuticals, Inc. (NRXP)
• Date: Tuesday, April 22nd, 2025, 10:00 AM EDT
• Webcast: https://ir.nrxpharma.com/events

Investors interested in watching the event can use the link above or contact their HC Wainwright representative to register. 

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional  psychiatry clinics to offer ketamine transcranial magnetics stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the satisfaction of closing conditions necessary to consummate the acquisition of Kadima and Dura, and obtaining financing necessary to consummate the acquisitions. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund such acquisitions, and the Company's ability to spin-off Hope Therapeutics.  More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-inc-nasdaqnrxp-and-hope-therapeutics-incto-participate-in-an-hc-wainwright--home-fireside-discussion-on-tuesday-april-22-2025-302432978.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

When is NRx Pharmaceuticals (NRXP) participating in the H.C. Wainwright fireside chat?

NRx Pharmaceuticals will participate in the H.C. Wainwright fireside chat on Tuesday, April 22, 2025, at 10:00 AM EDT.

How can investors access the NRXP H.C. Wainwright fireside discussion?

Investors can access the webcast through ir.nrxpharma.com/events or by contacting their HC Wainwright representative to register.

Who will represent NRXP at the H.C. Wainwright fireside chat?

Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx Pharmaceuticals and Co-CEO of HOPE Therapeutics, will represent the company.

What is the relationship between NRXP and HOPE Therapeutics?

HOPE Therapeutics is an interventional psychiatry network that is wholly owned by NRx Pharmaceuticals.